Amylyx Pharmaceuticals, Inc. AMLX

AMLX Company Overview

Amylyx Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for neurodegenerative, endocrine, and rare diseases. The company operates within the biotechnology and pharmaceutical industries, with a strategy centered on targeting disease mechanisms associated with cellular dysfunction, neuroinflammation, and metabolic stress. Amylyx became widely known through the development of AMX0035, marketed as RELYVRIO in the United States for amyotrophic lateral sclerosis (ALS) before its withdrawal from the market in 2024 following Phase 3 trial results that did not confirm clinical benefit. The company continues to advance a pipeline of investigational therapies across neurological and metabolic disorders.

Amylyx’s primary business activities include drug research and development, clinical trials, regulatory engagement, and commercialization efforts for approved or investigational therapies. Key pipeline assets have included avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism, as well as investigational programs targeting Wolfram syndrome and progressive supranuclear palsy. The company’s positioning has historically emphasized rapid development pathways for serious diseases with limited treatment options, supported by collaborations with academic researchers, patient advocacy groups, and specialized clinical centers. Amylyx was founded in 2013 by Joshua Cohen and Justin Klee and completed its initial public offering on Nasdaq in 2022 under the ticker AMLX.